Effect of taVNS of Brainstem Activation in Early and Late Parkinson's Disease Patients - an fMRI Study

• ClinicalTrials.gov Identifier: NCT05967598
• Recruitment Status: Completed
• First Posted: August 1, 2023
• Last Update Posted: October 17, 2023
• Sponsor: University of Ljubljana
• Collaborator: University Medical Centre Ljubljana
• Information provided by (Responsible Party): Andrej Vovk, University of Ljubljana

Study Description

Brief Summary:

This is a randomised, within-subject, double-blinded, placebo-controlled study to assess the fMRI correlates of central nervous system (CNS) response to taVNS in early vs late-stage Parkinsons disease (PD), at two different frequencies. Forty PD patients will be included: twenty patients with early-stage (Hoehn and Yahr stage (HY) 1-2) and twenty patients with late-stage (HY 3-4) PD. Each patient will undergo one stimulation session, where they will receive active taVNS at 100 Hz (taVNS100), taVNS at 25Hz (taVNS25) or will have positioned electrodes without stimulation (xVNS). The order of taVNS100, taVNS25 and xVNS will be randomized between subjects. The session will include (1) xVNS and taVNS; (2) MRI and fMRI and (3) heart rate and breathing rate monitoring. Clinical assessment with the Movement Disorder Society-Unified Parkinson's Disease Rating Scale will be done before the session.

Condition or disease	Intervention/treatment	Phase
Parkinson Disease; Neurologic Disorder	Device: Noninvasive transcutaneous auricular vagus nerve stimulation at 100Hz; Device: Noninvasive transcutaneous auricular vagus nerve stimulation at 25Hz; Device: Sham cyma conchae stimulation	Not Applicable

Detailed Description:

Each participant will complete 1 visit, where the investigators will first assess the MDS-UPDRS score, afther that the sesnsitivity threasholds for taVNS at 25Hz and taVNS at 100Hz will be assessed. The Nemos® electrode for taVNS will be positioned in the left cymba conchae with the following parameters: square-shaped pseudobiphasic pulse, interpulse duration 80μs, pulse width 300μs. taVNS25 will be applied at 25Hz and taVNS100 will be applied at 100Hz. The sensory threshold will be assessed for each frequency and in the MRI scanner a pulse intensity of 0,1mA above the perceptual threshold will be applied.

After that the participant will be escorted to the MRI scanner where the MRI-safe electrode will be positioned in the left cymba conchae. The participant will be instructed to hold their head still during the complete experiment and that they will receive 3 different electrical stimulation types during 3 separate sessions. They will be further instructed that a black dot that will appear on the screen before each stimulation session and that they should fix their gaze on the dot. The instructions will be repeated before each BOLD MRI session.

MRI will be performed at the Center for Clinical physiology at the Medical faculty in Ljubljana (Center za klinično fiziologijo; CKF), using a 3T Philips Achieva 3TX dStream (Best, The Netherlands).

The investigators will acquire high-resolution T1-weighted and T2-weighted (0.7 x 0.7 x 0.7 mm^3) volumes of the brain. The area of brainstem and cerebellum will be scanned using a T1-weighted spectral pre-saturation with inversion recovery (SPIR) sequence to enhance the contrast of neuromelanin structures (and better delineate LC). The three structural scans will be interspaced with 3 time slots, containing three 8 minutes long block design blood oxygen level-dependent (BOLD MRI; fMRI) sessions (~1.75mm^3 isometric voxel). During each fMRI slot participants will receive a different type of stimulation (taVNS,25, taVNS100 and xVNS). While the participant will receive electrical stimulation during taVNS25 and taVNS100, there will be no current applied during xVNS. To reduce any carryover effect the investigators will randomise the order of the 3 fMRI sessions. The order of stimulation will not be revealed until the automated data and statistical analysis.

The timeline of the complete imaging session would be as follows: Survey scan - Slot 1 - T1 - Slot 2 - T2 - Slot 3 - neuromelanin sequence. The session should last up to 60 min. During this time the investigators will monitor heart rate and breathing rate remotely.

For the analysis T1-weighted images will be first segmented into grey, white and cerebrospinal fluid (CSF) tissue compartments using DARTEL, implemented in SPM12. This also provides spatial normalization and co-registration to the standard MNI space. Images from other modalities will first be co-registered to T1-weighted structural scans and next to the MNI template as secondary images using the identical transform algorithm. From the fMRI data the investigators will analyse (i) brainstem activation patterns (ROI analysis); and (ii) block design connectivity between nucleus tractus solitarii and central nervous system (CNS) structures and locus coeruleus and CNS stuctures. fMRI analyses will be done with Analysis of Functional NeuroImages (AFNI) tools.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 40 participants
• Allocation: Randomized
• Intervention Model: Factorial Assignment

Intervention Model Description

40 participants with the diagnosis of PD patients aged > 45 years will be included. Patients will be recruited from the outpatient and inpatient clinics. PD will be diagnosed according to the UK PD Society Brain Bank criteria: the investigators aim to include 20 patients with early-stage and 20 patients with late-stage PD. Each participant will complete 1 visit at the MRI scanning facility, during which they will complete 3 blocks of 8min block design fMRI. During each block they will receive a different kind of stimulation (taVNS25, taVNS100, xVNS; see detailed description).

The effect will be compared within each group (early and advanced patients) and between groups (early vs advanced PD patients).

• Masking: Triple (Participant, Investigator, Outcomes Assessor)

Masking Description

Before the experiment the stimulation threshold (i.e. current) for each stimulation (taVNS25 and taVNS100) will be assessed by a third person.

The participant will be told, that the investigators are comparing the effect of 3 different stimulation types and that each will be delivered at a different intensity.

The order of stimulation will be randomised across the 3 fMRI slots by a third person and the stimulation type will be noted in a separate log file.

The outcomes assessor will be blinded to the stimulation type until the end of the analysis process.

• Primary Purpose: Basic Science
• Official Title: Effect of Transcutaneous Auricular Vagl Nerve Electrostimulation of Brainstem Structures in Early and Late Parkinson's Disease Patients - an fMRI Study
• Actual Study Start Date: February 15, 2023
• Actual Primary Completion Date: September 29, 2023
• Actual Study Completion Date: September 29, 2023

Arms and Interventions

Arm	Intervention/treatment
Active Comparator: taVNS100 in advanced PD patients; Noninvasive electrostimulation will be applied to the left cyma conchae through the Nemos® electrode at 100Hz to advanced PD patients. Participants will complete an 8 minute block design fMRI block.	Device: Noninvasive transcutaneous auricular vagus nerve stimulation at 100Hz; Noninvasive electrostimulation will be applied to the left cyma conchae through the Nemos® electrode with the following parameters: square-shaped pseudobiphasic pulse, interpulse duration 80μs, pulse width 300μs, pulse intensity 0,1mA above the perceptual threshold at 100Hz. The intensity for each separate stimulation will be adjusted for each participant at the beginning of the experiment; Other Name: taVNS100
Active Comparator: taVNS25 in advanced PD patients; Noninvasive electrostimulation will be applied to the left cyma conchae through the Nemos® electrode at 25Hz to advanced PD patients. Participants will complete an 8 minute block design fMRI block.	Device: Noninvasive transcutaneous auricular vagus nerve stimulation at 25Hz; Noninvasive electrostimulation will be applied to the left cyma conchae through the Nemos® electrode with the following parameters: square-shaped pseudobiphasic pulse, interpulse duration 80μs, pulse width 300μs, pulse intensity 0,1mA above the perceptual threshold at 25Hz. The intensity for each separate stimulation will be adjusted for each participant at the beginning of the experiment.; Other Name: taVNS25
Placebo Comparator: xVNS in advanced PD patients; The electrode will be placed in the left cyma conchae however no electrical current will be applied to advanced PD patients. Participants will complete an 8 minute block design fMRI block.	Device: Sham cyma conchae stimulation; The electrode will be placed at the cymba conchae location, however no electrical current will be applied. All other experimental conditions will be the same as for the active taVNS stimulation.; Other Name: xVNS
Active Comparator: taVNS100 in early PD patients; Noninvasive electrostimulation will be applied to the left cyma conchae through the Nemos® electrode at 100Hz to early PD patients. Participants will complete an 8 minute block design fMRI block.	Device: Noninvasive transcutaneous auricular vagus nerve stimulation at 100Hz; Noninvasive electrostimulation will be applied to the left cyma conchae through the Nemos® electrode with the following parameters: square-shaped pseudobiphasic pulse, interpulse duration 80μs, pulse width 300μs, pulse intensity 0,1mA above the perceptual threshold at 100Hz. The intensity for each separate stimulation will be adjusted for each participant at the beginning of the experiment; Other Name: taVNS100
Active Comparator: taVNS25 in early PD patients; Noninvasive electrostimulation will be applied to the left cyma conchae through the Nemos® electrode at 25Hz to early PD patients. Participants will complete an 8 minute block design fMRI block.	Device: Noninvasive transcutaneous auricular vagus nerve stimulation at 25Hz; Noninvasive electrostimulation will be applied to the left cyma conchae through the Nemos® electrode with the following parameters: square-shaped pseudobiphasic pulse, interpulse duration 80μs, pulse width 300μs, pulse intensity 0,1mA above the perceptual threshold at 25Hz. The intensity for each separate stimulation will be adjusted for each participant at the beginning of the experiment.; Other Name: taVNS25
Placebo Comparator: xVNS in early PD patients; The electrode will be placed in the left cyma conchae however no electrical current will be applied to early PD patients. Participants will complete an 8 minute block design fMRI block.	Device: Sham cyma conchae stimulation; The electrode will be placed at the cymba conchae location, however no electrical current will be applied. All other experimental conditions will be the same as for the active taVNS stimulation.; Other Name: xVNS

Outcome Measures

Primary Outcome Measures :

1. Comparison of Brainstem activation pattern on fMRI (ROI analysis) during taVNS compared to xVNS [ Time Frame: Only the online/acute effect measured during stimulation (time frame duration of 8 minutes per stimulation type) will be analysed. ]
   Block-design fMRI analysis will be performed on brainstem ROIs to assess activation in neuromodulatory brainstem nuclei during taVNS compared with xVNS using the tools of the AFNI program. Final analysis will be performed on group level.
2. Comparison of Functional connectivity pattern on fMRI (block design) of nucleus tractus solitarii and the rest of the nervous system during taVNS compared to xVNS [ Time Frame: Only the online/acute effect measured during stimulation (time frame duration of 8 minutes per stimulation type) will be analysed. ]
   Functional connectivity (fMRI, block design) between the nucleus tractus solitarii (NTS) and the rest of the central nervous system will be analysed with AFNI Context-Dependent Correlation Analysis to determine whether taVNS produces a different pattern of connectivity compared with xVNS.
3. Comparison of Functional connectivity pattern on fMRI (block design) of locus coeruleus (LC) and the rest of the nervous system during taVNS compared to xVNS [ Time Frame: Only the online/acute effect measured during stimulation (time frame duration of 8 minutes per stimulation type) will be analysed. ]
   Functional connectivity pattern (fMRI, block design) between the nucleus locus coeruleus (LC) and the rest of the central nervous system will be analysed with AFNI Context-Dependent Correlation Analysis to determine whether taVNS produces a different pattern of connectivity compared with xVNS.

Secondary Outcome Measures :

1. Comparison of Brainstem activation pattern on fMRI (ROI analysis) during taVNS25 compared to taVNS100 [ Time Frame: Only the online/acute effect measured during stimulation (time frame duration of 8 minutes per stimulation type) will be analysed. ]
   Block-design fMRI analysis will be performed on brainstem ROIs to assess activation in neuromodulatory brainstem nuclei during taVNS100 compared with taVNS25 using the tools of the AFNI program. Final analysis will be performed on group level.
2. Comparison of Functional connectivity pattern on fMRI (block design) of nucleus tractus solitarii and the rest of the nervous system during taVNS25 compared to taVNS100 [ Time Frame: Only the online/acute effect measured during stimulation (time frame duration of 8 minutes per stimulation type) will be analysed. ]
   Functional connectivity (fMRI, block design) between the nucleus tractus solitarii (NTS) and the rest of the central nervous system will be analysed with AFNI Context-Dependent Correlation Analysis to determine whether taVNS produces a different pattern of connectivity compared with xVNS.
3. Comparison of Functional connectivity pattern on fMRI (block design) of locus coeruleus (LC) and the rest of the nervous system during taVNS100 compared to taVNS25 [ Time Frame: Only the online/acute effect measured during stimulation (time frame duration of 8 minutes per stimulation type) will be analysed. ]
   Functional connectivity pattern (fMRI, block design) between the nucleus locus coeruleus (LC) and the rest of the central nervous system will be analysed with AFNI Context-Dependent Correlation Analysis to determine whether taVNS100 produces a different pattern of connectivity compared with taVNS25.

Eligibility Criteria

• Ages Eligible for Study: 45 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• diagnosis of Parkinson's disease according to the UK PD Society Brain Bank criteria
• ability to walk independently for at least 2 minutes
• cognitive impairment that might prevent cooperation during tests
• stable antiparkinsonian medications during the previous 1 month

Exclusion Criteria:

• medication resistant rest tremor or dyskinesias
• history of seizures
• implanted medical devices or metal implants
• pregnancy
• claustrophobia
• fixed or severe kyphosis
• any conditions that would prevent our patients from lying still for 1 hour in a supine position (i.e. muscle pain, degenerative joint diseases…).

Contacts and Locations

Locations

Slovenia

Neurology Department, UMC Ljubljana

Ljubljana, Slovenia, 1000

Sponsors and Collaborators

University of Ljubljana

University Medical Centre Ljubljana

Investigators

• Principal Investigator: Andrej Vovk, PhD; Medical Faculty, University of Ljubljana

More Information

• Responsible Party: Andrej Vovk, Principal investigator, University of Ljubljana
• ClinicalTrials.gov Identifier: NCT05967598
• Other Study ID Numbers: 012052/2020-2
• First Posted: August 1, 2023
• Last Update Posted: October 17, 2023
• Last Verified: October 2023

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: Yes
• Plan Description: The investigators plan to share the anonymised data with researchers upon request.
• Supporting Materials: Study Protocol; Statistical Analysis Plan (SAP); Informed Consent Form (ICF); Analytic Code
• Time Frame: Upon request after study publication
• Access Criteria: Data will be shared with researchers upon reasonable request

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Andrej Vovk, University of Ljubljana:

Parkinson disease; taVNS; transcutaneous auricular vagal nerve stimulation; fMRI; brainstem ROI analysis

Additional relevant MeSH terms:

Parkinson Disease; Nervous System Diseases; Parkinsonian Disorders; Basal Ganglia Diseases; Brain Diseases; Central Nervous System Diseases; Movement Disorders; Synucleinopathies; Neurodegenerative Diseases